Momelotinib - Sierra Oncology

Drug Profile

Momelotinib - Sierra Oncology

Alternative Names: CYT-387; GS-0387; Momelotinib dihydrochloride

Latest Information Update: 09 Nov 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Cytopia Research
  • Developer Gilead Sciences
  • Class Antineoplastics; Benzamides; Morpholines; Pyrimidines; Small molecules
  • Mechanism of Action ACVR1 protein inhibitors; Janus kinase 1 inhibitors; Janus kinase-2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Myeloproliferative disorders
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase III Essential thrombocythaemia; Myelofibrosis; Myeloproliferative disorders; Pancreatic cancer; Polycythaemia vera
  • No development reported Non-small cell lung cancer

Most Recent Events

  • 01 Nov 2018 Efficacy, adverse events and pharmacodynamics data from a phase II trial in Myelofibrosis, Polycythemia vera and Essential thrombocythemia released by Sierra Oncology
  • 22 Aug 2018 Gilead Sciences completes the phase III Simplify 2 trial in Myelofibrosis in Canada, France, Germany, Israel, Italy, Spain, United Kingdom and the US before August 2018
  • 22 Aug 2018 Sierra Oncology acquires momelotinib from Gilead Sciences
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top